Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Zentek Ltd. (ZEN.V)
CAD0.66
+0.02 (+3.13%)
CA TSXV Healthcare Medical - Instruments & Supplies
Address
1205 Amber Drive P7B 6M4
Guelph, ON, CA
Guelph, ON, CA
CEO
Mohammed Jiwan
Website
zentek.com
IPO
2010-12-23
ISIN CA98942X1024
Also trades on
NASDAQ Capital Market · ZTEK (USD)
Toronto Stock Exchange Ventures · ZEN.V (CAD)
Description
Zentek Ltd. is a Canadian company focused on the exploration and advancement of graphene and related nanomaterials. It fully owns the Albany Graphite project, situated in Northern Ontario, Canada. The firm develops its ZenGUARD brand, a graphene-based antimicrobial coating, incorporating it into products like surgical masks, HVAC filters, and personal protective equipment. Additionally, Zentek's innovation extends to rapid detection point-of-care diagnostics and pharmaceutical products, all leveraging graphene-based compounds. The company also specializes in synthesizing graphene, graphene oxide, and graphene quantum dots for diverse applications. Founded in 2008 and headquartered in Thunder Bay, Canada, Zentek Ltd. was formerly known as ZEN Graphene Solutions Ltd. until its name change in October 2021.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CAD0.66
+0.02 (+3.13%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
247.7K
Beta
0.29
Float Shares
102.68M
Free Float %
95.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.66% | -15.96% | +33.90% | +0.00% | -29.46% | -11.24% | -62.38% | -64.73% | -70.52% | +5.33% | +29.51% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.66
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
1.88
Grey zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Instruments & Supplies: +7.9%-81.0% Q1'26: -95.5% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%+5.4% Q1'26: -85.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%-5,793.9% Q1'26: -2,473.2% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%-6,521.6% Q1'26: -10,456.1% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%-104.0% Q1'26: -147.7% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+2.9% Q1'26: +3.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×-0.19× Q1'26: -0.13× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
Mar 2031 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
339.7K
est: 1.00M (-66.0%)
|
72.9K
est: 3.50M (-97.9%)
|
29.8K
est: 14.00M (-99.8%)
|
872.5K
est: 872.5K (+0.0%)
|
116.8K
116.8K – 116.8K
-86.6% YoY
|
82.2K
82.2K – 82.2K
-29.6% YoY
|
1.00M
1.00M – 1.00M
+1,116.8% YoY
|
3.50M
3.50M – 3.50M
+250.0% YoY
|
14.00M
14.00M – 14.00M
+300.0% YoY
|
| EBITDA |
-11.27M
est: -1.00M (-1,027.3%)
|
-13.75M
est: -3.50M (-293.0%)
|
-11.08M
est: -14.00M (+20.9%)
|
-9.35M
est: -872.5K (-971.4%)
|
-116.8K
-116.8K – -116.8K
+86.6% YoY
|
-82.2K
-82.2K – -82.2K
+29.6% YoY
|
-1.00M
-1.00M – -1.00M
-1,116.8% YoY
|
-3.50M
-3.50M – -3.50M
-250.0% YoY
|
-14.00M
-14.00M – -14.00M
-300.0% YoY
|
| EBIT |
-11.89M
est: -1.00M (-1,088.8%)
|
-14.29M
est: -3.50M (-308.4%)
|
-11.70M
est: -14.00M (+16.5%)
|
-9.95M
est: -872.5K (-1,040.2%)
|
-116.8K
-116.8K – -116.8K
+86.6% YoY
|
-82.2K
-82.2K – -82.2K
+29.6% YoY
|
-1.00M
-1.00M – -1.00M
-1,116.8% YoY
|
-3.50M
-3.50M – -3.50M
-250.0% YoY
|
-14.00M
-14.00M – -14.00M
-300.0% YoY
|
| Net Income |
-38.69M
est: -10.30M (-275.8%)
|
-14.41M
est: -15.45M (+6.7%)
|
-11.70M
est: -10.30M (-13.7%)
|
-10.04M
|
-4.24M
-4.24M – -4.24M
|
-4.24M
-4.24M – -4.24M
+0.0% YoY
|
-10.59M
-10.59M – -10.59M
-150.0% YoY
|
-15.89M
-15.89M – -15.89M
-50.0% YoY
|
-10.59M
-10.59M – -10.59M
+33.3% YoY
|
| SGA |
9.56M
est: 453.81M (-97.9%)
|
10.93M
est: 1.59B (-99.3%)
|
8.95M
est: 6.35B (-99.9%)
|
8.01M
est: 395.94M (-98.0%)
|
11.79M
11.79M – 11.79M
-97.0% YoY
|
8.29M
8.29M – 8.29M
-29.6% YoY
|
100.93M
100.93M – 100.93M
+1,116.8% YoY
|
353.25M
353.25M – 353.25M
+250.0% YoY
|
1.41B
1.41B – 1.41B
+300.0% YoY
|
| EPS |
-0.42
est: -0.10 (-320.0%)
|
-0.14
est: -0.15 (+6.7%)
|
-0.12
est: -0.10 (-20.0%)
|
-0.10
|
-0.04
-0.04 – -0.04
|
-0.04
-0.04 – -0.04
+0.0% YoY
|
-0.10
-0.10 – -0.10
-150.0% YoY
|
-0.15
-0.15 – -0.15
-50.0% YoY
|
-0.10
-0.10 – -0.10
+33.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
77.51M
OE per share TTM
0.75
Owner's Yield
91.90%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
9,508.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-4.5K
Shares Outstanding
107.54M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mohammed Jiwan | Chief Executive Officer & Director | 325.0K | male |
| Wendy Ford | Chief Financial Officer | 252.0K | female |
| Ryan Shacklock | Senior Vice President of Strategy & Business Development | 175.0K | male |
| Eric Wallman | Board Secretary & Director | 97.5K | male |
| John Snisarenko | Secretary & Board Chair | 45.0K | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ZEN.V
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
